Cargando…

Advances in deubiquitinating enzymes in lung adenocarcinoma

The process of ubiquitination and deubiquitination is widely present in the human body's protein reactions and plays versatile roles in multiple diseases. Deubiquitinating enzymes (DUBs) are significant regulators of this process, which cleave the ubiquitin (Ub) moiety from various substrates a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xi-Jia, Li, Rui, Liu, Xiao, Qu, Yi-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364634/
https://www.ncbi.nlm.nih.gov/pubmed/34405018
http://dx.doi.org/10.7150/jca.56532
_version_ 1783738555036598272
author Zhou, Xi-Jia
Li, Rui
Liu, Xiao
Qu, Yi-Qing
author_facet Zhou, Xi-Jia
Li, Rui
Liu, Xiao
Qu, Yi-Qing
author_sort Zhou, Xi-Jia
collection PubMed
description The process of ubiquitination and deubiquitination is widely present in the human body's protein reactions and plays versatile roles in multiple diseases. Deubiquitinating enzymes (DUBs) are significant regulators of this process, which cleave the ubiquitin (Ub) moiety from various substrates and maintain protein stability. Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer (NSCLC) and remains refractory to treatment. To elucidate the mechanism of LUAD and advance new therapeutic targets, we review the latest research progress on DUBs in LUAD. We summarize the biological capabilities of these DUBs and further highlight those DUBs that may serve as anticancer target candidates for precision treatment. We also discuss deubiquitinase inhibitors, which are expected to play a role in targeted LUAD therapy.
format Online
Article
Text
id pubmed-8364634
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-83646342021-08-16 Advances in deubiquitinating enzymes in lung adenocarcinoma Zhou, Xi-Jia Li, Rui Liu, Xiao Qu, Yi-Qing J Cancer Review The process of ubiquitination and deubiquitination is widely present in the human body's protein reactions and plays versatile roles in multiple diseases. Deubiquitinating enzymes (DUBs) are significant regulators of this process, which cleave the ubiquitin (Ub) moiety from various substrates and maintain protein stability. Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer (NSCLC) and remains refractory to treatment. To elucidate the mechanism of LUAD and advance new therapeutic targets, we review the latest research progress on DUBs in LUAD. We summarize the biological capabilities of these DUBs and further highlight those DUBs that may serve as anticancer target candidates for precision treatment. We also discuss deubiquitinase inhibitors, which are expected to play a role in targeted LUAD therapy. Ivyspring International Publisher 2021-07-25 /pmc/articles/PMC8364634/ /pubmed/34405018 http://dx.doi.org/10.7150/jca.56532 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Zhou, Xi-Jia
Li, Rui
Liu, Xiao
Qu, Yi-Qing
Advances in deubiquitinating enzymes in lung adenocarcinoma
title Advances in deubiquitinating enzymes in lung adenocarcinoma
title_full Advances in deubiquitinating enzymes in lung adenocarcinoma
title_fullStr Advances in deubiquitinating enzymes in lung adenocarcinoma
title_full_unstemmed Advances in deubiquitinating enzymes in lung adenocarcinoma
title_short Advances in deubiquitinating enzymes in lung adenocarcinoma
title_sort advances in deubiquitinating enzymes in lung adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364634/
https://www.ncbi.nlm.nih.gov/pubmed/34405018
http://dx.doi.org/10.7150/jca.56532
work_keys_str_mv AT zhouxijia advancesindeubiquitinatingenzymesinlungadenocarcinoma
AT lirui advancesindeubiquitinatingenzymesinlungadenocarcinoma
AT liuxiao advancesindeubiquitinatingenzymesinlungadenocarcinoma
AT quyiqing advancesindeubiquitinatingenzymesinlungadenocarcinoma